A Randomized, Double-blind, Multicenter, Phase II Study to Assess the Safety, Tolerability, and Efficacy of ZD6474 in Combination With Docetaxel (TAXOTERE™) in Subjects With Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) After Failure of Prior Platinum-based Chemotherapy.
Interventional
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment
Outcome Progression free survival
ZD6474 Medical Science Director, MD
Study Director
AstraZeneca
United States: Food and Drug Administration
6474IL/0006
NCT00047840
October 2002
September 2006
Name | Location |
---|---|
Research Site | Anaheim, California |
Research Site | Boca Raton, Florida |
Research Site | Albany, Georgia |
Research Site | Baton Rouge, Louisiana |
Research Site | Beverly, Massachusetts |
Research Site | Battle Kreek, Michigan |
Research Site | Billings, Montana |
Research Site | Albany, New York |
Research Site | Asheville, North Carolina |
Research Site | Bend, Oregon |
Research Site | Allentown, Pennsylvania |
Research Site | Abilene, Texas |